



THERMOGENESIS NAMES JORGE ARTILES

VICE PRESIDENT, CHIEF QUALITY AND REGULATORY AFFAIRS OFFICER

EXECUTIVE HAS MORE THAN TWO DECADES OF MEDICAL DEVICE EXPERIENCE

(RANCHO CORDOVA, CA), October 19, 2009—ThermoGenesis (NASDAQ: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, said today that Jorge F. Artiles has joined the Company as Vice President, Chief Quality and Regulatory Affairs Officer, effective immediately.

Artiles has more than two decades of quality and regulatory affairs experience in the medical device industry, with expertise in quality system development and compliance, project management and process optimization.

Most recently, Artiles was Vice President, Quality Assurance and Regulatory Affairs, for Physio Control, a division of Medtronic. Before that, he held a similar position at Cytoc Surgical Products, where he was responsible for quality and regulatory affairs at two manufacturing sites. Artiles has also held quality and regulatory management positions with Teleflex Medical, Abbott Laboratories, Boston Scientific and Baxter Healthcare. He holds a B.S. in Industrial Technology and an M.S. in Quality Assurance and Industrial Technology from San Jose State University.

“While we have made significant progress with our product quality initiatives over the past year, Jorge brings a level of expertise and experience that will be critical to our growth as we expand our product offerings and develop new market opportunities,” said J. Melville Engle, Chief Executive Officer of ThermoGenesis.

“He has extensive experience in developing and managing quality assurance programs and procedures, implementing sourcing, manufacturing and cost control initiatives and ensuring regulatory compliance within both large organizations and at a divisional level,” Engle added.

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

- **The BioArchive[®] System**, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant.

- **AXP[®] AutoXpress[™] Platform (AXP)**, a proprietary family of automated devices that includes the AXP and the MXP[™] MarrowXpress[™] and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. GE Healthcare is the exclusive global distribution partner for the AXP cord blood product except for Central and South America, China (except Hong Kong), Russia/CIS and Japan, where ThermoGenesis markets through independent distributors. The MXP is used for isolating stem cells from bone marrow.
- **The Res-Q[™] 60 BMC (Res-Q)**, a point of care system that is designed for bone marrow stem cell processing. This product was launched in July 2009.
- **The CryoSeal[®] FS System**, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community. Asahi Medical is the exclusive distributor for the CryoSeal System in Japan and the Company markets through independent distributors in Europe and South America.

This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal years 2010, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2010. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.

Web site: <http://www.thermogenesis.com>

Contact: Investor Relations

+1-916-858-5107, or

ir@thermogenesis.com